Testing a new drug for Sjögren's syndrome with lung disease
Treatments studied
Part of Bones, joints & muscles, Eyes & vision, Immune system & allergy, Lungs & breathing, Mouth & dental, Skin clinical trials.
This clinical trial tests a new drug called telitacicept for people who have both Sjögren's syndrome and interstitial lung disease. The drug aims to reduce the immune system's attack on your body and may help improve lung symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old
- You must have a confirmed diagnosis of Sjögren's syndrome
- You must have interstitial lung disease confirmed by a special scan
- You must be on a stable dose of your current medications for at least 1 week
- You must not have other autoimmune diseases like lupus or rheumatoid arthritis
- You must not have taken certain biologic drugs in the last 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called IBI355 for people with moderate-to-severe Sjögren's disease. It aims to reduce inflammation and improve symptoms by targeting part of the immune system.
This trial tests if a new drug called telitacicept works better than a standard lupus medicine (cyclophosphamide) to improve lupus-related lung scarring (interstitial lung disease). It might be an option if your breathing tests are still good enough.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This trial tests a new drug called telitacicept for people with lung scarring caused by connective tissue diseases. It aims to see if the drug can improve lung function and slow down the disease progression.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't improved after trying multiple treatments. It aims to see if the drug can reduce joint pain and swelling when other medications have failed.
This study tests an investigational drug called CM336 for people with active Sjögren's syndrome. It aims to see if the drug is safe and effective in reducing symptoms like joint pain and dryness when other treatments haven't worked well.
Hear when a new Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.